摘要
目的探究依达拉奉右莰醇联合阿托伐他汀对大动脉粥样硬化型脑梗死(large artery atherosclerosis stroke,LAAS)患者的临床疗效。方法选取收治的110例LAAS患者作为研究对象,采用随机数字表法分为对照组和观察组,每组55例。对照组给予阿托伐他汀治疗,观察组在对照组用药的基础上加用依达拉奉右莰醇。比较2组患者的临床疗效、改良Rankin量表(modified Rankin Scale,mRS)评分、改良Barthel指数量表(modified Barthel Index,mBI)评分、脂代谢指标[三酰甘油(triglyceride,TG)、总胆固醇(total cholesterol,TC)、低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)]、炎症因子[超敏C反应蛋白(high sensitivity C-reactive protein,hs-CRP)、白细胞介素-6(interleukin-6,IL-6)]及可溶性生长刺激表达基因2蛋白(soluble growth stimulation expressed gene 2,sST2)的水平。结果观察组的总有效率显著高于对照组(P<0.05);治疗后,2组的mBI评分均显著升高,且观察组高于对照组(P<0.05);2组的mRS评分,TG、TC、LDL-C、hs-CRP、IL-6、sST2水平均显著降低,且观察组均低于对照组(P<0.05)。结论依达拉奉右莰醇联合阿托伐他汀治疗LAAS的疗效显著优于单药治疗,可显著改善患者的神经功能、生活能力及炎症状态,调节脂代谢水平。
Objective To explore the effect of edaravone-dexborneol combined with atorvastatin in patients with large artery atherosclerosis stroke(LAAS).Methods 110 LAAS patients were randomly divided into 2 groups.The control group(55 cases)was given atorvastatin,while the observation group(55 cases)was given edaravone-dexborneol in addition to the control group.The clinical efficacy,modified Rankin Scale(mRS),modified Barthel Index(mBI)score,lipid metabolism[triglyceride(TG),total cholesterol(TC),and low-density lipoprotein cholesterol(LDL-C)],inflammatory factors[high-sensitivity C-reactive protein(hs-CRP)and interleukin-6(IL-6)],and soluble growth stimulation expressed gene 2(sST2)levels between the 2 groups were compared.Results The total effective rate of the observation group was higher than the control group(P<0.05);after treatment,the mBI scores of the 2 groups increased,while the mRS score,TG,TC,LDL-C,hs-CRP,IL-6,and sST2 levels decreased,which were more obvious in the observation group than in the control group,respectively(P<0.05).Conclusion Edaravone dexborneol combined with atorvastatin has good clinical efficacy in the treatment of LAAS.It can reduce the levels of sST2,lipid metabolism,and inflammatory factors,and improve neurological function and daily living ability.
作者
温慧灵
黄晓勇
崔春霞
WEN Huiling;HUANG Xiaoyong;CUI Chunxia(Department of Emergency,Haian People’s Hospital,Haian 226600,China)
出处
《西北药学杂志》
2025年第4期87-92,共6页
Northwest Pharmaceutical Journal
基金
海安市人民医院院级科研项目(编号:202334)。
